FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser: Davidson Kempner Capital Management LP
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):
        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
 
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:
        Use a separate form for each offeror/offeree
easyJet plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  
(e)   Date position held/dealing undertaken:
        For an opening position disclosure, state the latest practicable date prior to the disclosure
24/09/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?
        If it is a cash offer or possible cash offer, state “N/A”
No

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security: 27 2/7p ordinary
(ISIN-GB00B7KR2P84)
  Interests Short positions
Number % Number %
(1)   Relevant securities owned and/or controlled:        
(2)   Cash-settled derivatives: 16,302,925 2.15%    
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:        
        TOTAL: 16,302,925 2.15%    

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:  
Details, including nature of the rights concerned and relevant percentages:  

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchase/sale Number of securities Price per unit

(b)        Cash-settled derivative transactions

Class of relevant security Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities Price per unit
27 2/7p ordinary CFD Increasing a long position 351,355 GBP 6.7000

        
(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
e.g. American, European etc.
Expiry date Option money paid/ received per unit

(ii)        Exercise

Class of relevant security Product description
e.g. call option
Exercising/ exercised against Number of securities Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing
e.g. subscription, conversion
Details Price per unit (if applicable)

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
(i)   the voting rights of any relevant securities under any option; or
(ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”

None

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached? NO

Date of disclosure: 25/09/2026
Contact name: Alex McMillan
Telephone number: 646 282 5805

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

EVANSVILLE, Ind., Sept. 25, 2026 (GLOBE NEWSWIRE) — (NASDAQ: ONB) – Old National Bancorp (“Old National”), the holding company of Old National Bank, today announced the following schedule for its third-quarter earnings release and conference call:

Earnings Release: Wednesday, October 21, 2026, at approximately 7:00 A.M. ET
   
Conference Call: Wednesday, October 21, 2026, at 10:00 A.M. ET
   
Dial-in Numbers: U.S. (833) 461-5787; International: (585) 542-9983; Meeting ID 244 307 806
   
Webcast: Via Old National’s Investor Relations website at oldnational.com
   
Webcast Replay: Available approximately two hours after completion of the call, until midnight ET on October 21, 2027, via Old National’s Investor Relations website at oldnational.com


ABOUT OLD NATIONAL

Old National Bancorp is the holding company of Old National Bank. As the sixth largest commercial bank headquartered in the Midwest, Old National proudly serves clients primarily in the Midwest and Southeast. With approximately $74 billion of assets and $41 billion of assets under management, Old National ranks among the top 25 banking companies headquartered in the United States. Tracing our roots to 1834, Old National focuses on building long-term, highly valued partnerships with clients while also strengthening and supporting the communities we serve. In addition to providing extensive services in consumer and commercial banking, Old National offers comprehensive wealth management and capital markets services. For more information and financial data, please visit Investor Relations at oldnational.com. In 2026, Points of Light named Old National to “The Civic 50” for the third consecutive year – an honor recognizing the 50 most community-minded companies in the United States – and also named Old National the Financials Sector Leader among nominated banks and financial services organizations.

Investor Relations:
Lynell Durchholz
(812) 464-1366
lynell.durchholz@oldnational.com

Media Relations:
Scott Reinhard
(612) 716-0304
scott.reinhard@oldnational.com

Robotics PR Cover

At IROS 2026, Seyond will showcase how premium, production-ready LiDAR is supporting robotics as autonomous systems move from specialized applications toward broader real-world deployment

SUNNYVALE, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) — As the global robotics community gathers for the 2026 IEEE/RSJ International Conference on Intelligent Robots and Systems (IROS), Seyond is highlighting a transformation already taking place beyond the research lab: robots are becoming an increasingly practical part of everyday life.

Across hospitals, warehouses, sidewalks, and commercial spaces, robots are taking on a growing range of real-world tasks. As the industry moves from prototypes and limited deployments toward broader commercialization, the challenge is no longer simply proving that a robot can navigate autonomously. It is doing so reliably, repeatedly and at meaningful scale.

Seyond is supporting this transition by bringing premium LiDAR technology to applications including healthcare and delivery robots, autonomous forklifts, AMRs, warehouse automation, humanoid robots, and other intelligent robotic platforms.

From Robotics Projects to Real-World Scale

The next wave of robotics growth is not being driven by a single type of robot.

In healthcare environments, autonomous mobile robots can transport medications, supplies, meals, and other materials throughout busy facilities. On sidewalks, delivery robots are bringing food and everyday goods directly to consumers. Across warehouses and logistics facilities, autonomous forklifts and AMRs are moving pallets, packages, and inventory alongside workers.

While these applications are different, they share a common challenge: robots must reliably understand and navigate dynamic environments designed around people.

For Seyond, the opportunity goes beyond supporting one or two robotics projects. As manufacturers move toward larger deployments, they need sensing technology that can meet production requirements without compromising the performance and reliability required for real-world autonomy.

Seyond’s approach is centered on delivering premium LiDAR performance at production scale, balancing sensing performance, quality, integration, reliability, and scalability. With more than one million sensors delivered across its broader business, Seyond brings established manufacturing experience to a robotics market entering its next stage of growth.

Premium Perception, Built for Robotics

Seyond’s robotics portfolio provides high-quality 3D sensing across different form factors, ranges, fields of view, and integration requirements.

The Hummingbird D1R, designed specifically for robotics applications, combines a compact form factor with a 140° × 100° field of view and close-range detection, supporting robotic platforms that need broad environmental awareness within limited installation space.

Seyond is also continuing to expand its robotics sensing portfolio toward even smaller, lighter, and more energy-efficient form factors. These ultra-compact sensing solutions are being developed for emerging space- and power-constrained robotic platforms, where every gram, millimeter, and watt can matter.

As robots become smaller, more capable, and more integrated into everyday environments, Seyond is working to make high-quality 3D perception easier to integrate across an increasingly diverse range of robotic systems.

See Seyond at IROS 2026

At the 2026 IEEE/RSJ International Conference on Intelligent Robots and Systems (IROS), Seyond will showcase its latest robotics sensing technologies and demonstrate how its LiDAR portfolio supports applications ranging from industrial automation and autonomous material handling to emerging robots designed to operate alongside people.

Visitors can meet the Seyond team at Booth 928 to explore how high-performance LiDAR can support the next generation of intelligent robotic systems.

The future of robotics will not be defined by a handful of prototypes, but by robots performing useful work at meaningful scale across the places where people live, work, receive care, and move through their day. Seyond is building the sensing technology to help make that transition possible.

About Seyond

Seyond is a global provider of advanced LiDAR solutions for automotive, robotics, and intelligent infrastructure applications. Focused on performance, reliability, and scalability, Seyond’s LiDAR technologies enable real-world autonomy across diverse operating environments. The company is committed to accelerating the adoption of safe, intelligent, and connected systems through next-generation 3D sensing.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/72d1cb74-198b-479a-a1c6-a529897ed357

CONTACT: PR Contact:
Seyond Marketing Team
PR@seyond.com

MONTREAL, Sept. 25, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it has ranked No. 345 on the 2026 Report on Business magazine’s ranking of Canada’s Top Growing Companies.

Canada’s Top Growing Companies ranks Canadian companies on three-year revenue growth. Knight earned its spot with three-year growth of 53%.

“We’re honored to be recognized as one of Canada’s Top Growing Companies by Report on Business for the sixth consecutive year,” said Samira Sakhia, President and CEO of Knight. “This recognition belongs to our team across Canada and Latin America. Their focus and disciplined execution continue to drive Knight’s growth. We remain committed to bringing innovative products to physicians and improving the health of the patients they serve. With over 50 product launches completed or planned across Canada and Latin America, we are well positioned to build on this momentum.”

Canada’s Top Growing Companies is an editorial ranking that was launched in 2019 to celebrate the achievements of innovative businesses in Canada. To qualify for this voluntary program; companies had to complete an in-depth application process and fulfill revenue requirements. In total, 375 companies earned a spot on this year’s ranking.

The full list of 2026 winners along with editorial coverage is published in the October issue of Report on Business magazine. The list is also published online here.

“Our annual ranking of Canada’s Top Growing Companies celebrates the innovation, ambition and resilience of businesses across the country, and we’re always excited to share as many of these standout stories as we can – including insight from the entrepreneurs themselves on how other companies can succeed, too.” says Dawn Calleja, editor of Report on Business magazine.

“The Globe and Mail congratulates the winners of Canada’s Top Growing Companies 2026 on this exceptional achievement,” says Andrew Saunders, president and CEO of The Globe and Mail. “Each of these organizations has shown an extraordinary ability to adapt, innovate and grow amid ongoing change. Their achievements reflect the ingenuity and determination of Canadian entrepreneurs and business leaders who are helping shape the future of our economy.”

About The Globe and Mail

The Globe and Mail is Canada’s foremost news media company, leading the national discussion and causing policy change through brave and independent journalism since 1844. With our award-winning coverage of business, politics and national affairs, The Globe and Mail newspaper reaches 6.1 million readers every week in our print or digital formats, and Report on Business magazine reaches 2.7 million readers in print and digital every issue. Our investment in innovative data science means that as the world continues to change, so does The Globe. The Globe and Mail is owned by Woodbridge, the investment arm of the Thomson family.

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring, in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.’s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.

Forward-Looking Statement

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Information Form for the year ended December 31, 2025, as filed on www.sedarplus.ca. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law.

Investor Contact:    
Knight Therapeutics Inc.    
     
Samira Sakhia   Arvind Utchanah
President & Chief Executive Officer   Chief Financial Officer
T: 514.484.4483   T: 514.484.4483
Email: IR@knighttx.com   Email: IR@knighttx.com
Website: www.knighttx.com   Website: www.knighttx.com

This press release was published by a CLEAR® Verified individual.

MISSISSAUGA, Ontario, Sept. 25, 2026 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that it has been named as one of Canada’s Top Growing Companies for 2026 by The Globe and Mail’s Report on Business magazine. BioSyent ranked 343 on the list based on its three-year revenue growth of 54% (2022 – 2025) and is listed in the ‘Consumer’ category.

“We are very proud to have been recognized as one of Canada’s Top Growing Companies,” said René Goehrum, President and CEO of BioSyent. “With the support of our team and the continued trust of patients and healthcare providers, we have continued to execute on one of BioSyent’s key strategic priorities of profitable growth, with Q2 2026 marking the 64th consecutive profitable quarter for the Company.”

The full 2026 ranking of Canada’s Top Growing Companies is available online at globeandmail.com and will appear in the October issue of Report on Business magazine.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty healthcare products company focused on acquiring or in-licensing, marketing and distributing innovative pharmaceutical and oral health products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its Pharmaceutical and Oral Health businesses, both in Canada and internationally.

As of the date of this press release, the Company has 11,232,335 common shares outstanding.

For a direct market quote for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

For further information please contact:
Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: investors@biosyent.com
Phone: 905-206-0013
Web: www.biosyent.com

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

SHANGHAI, China, Sept. 25, 2026 (GLOBE NEWSWIRE) — Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, has released its 2026 interim report, highlighting continued progress in its “AI + Chronic Disease Services” strategy as the Company advances its positioning as a full-lifecycle personal health service partner.

In the first half of 2026, Fangzhou recorded revenue of RMB1.8245 billion, up 22.2% year-on-year, while adjusted net profit increased 6.4% to RMB18.7 million. The Company’s cumulative registered users exceeded 59.8 million, with average monthly active users rising 23.1% to 14.7 million. Its network of registered physicians expanded to 282,000.

Fangzhou continued to accelerate the deployment of AI across chronic disease services, addressing persistent challenges in out-of-hospital management, including treatment adherence, patient follow-up and care costs. Built on its proprietary “XingShi” Large Language Model (“XS LLM”), its AI Health Manager and AI Medication Assistant provide 24/7 support, medication reminders and personalized health management based on patients’ evolving needs, helping shift chronic care from passive response toward proactive, continuous support.

On the physician side, AI pre-consultation, AI-assisted diagnosis and the AI Academic Assistant help reduce repetitive administrative workloads and improve service efficiency. Digital tools also support post-consultation follow-up, allowing professional medical services to reach more patients. Internally, Fangzhou has extended AI applications into supply-chain management, including inventory allocation and last-mile delivery, to improve operational efficiency.

The Company also continued strengthening the industry ecosystem underpinning its healthcare services. During the period, Fangzhou worked with more than 1,800 suppliers and 1,000 pharmaceutical companies, while prescription drugs accounted for 83.1% of platform GMV. Strategic collaborations with pharmaceutical companies, including Youcare Pharmaceutical and Tenry Pharma, supported the launch of innovative medicines, helping connect pharmaceutical innovation with patients through Fangzhou’s digital healthcare infrastructure.

Leveraging its patient network and digital engagement capabilities, Fangzhou is also expanding its role as a digital collaboration partner for pharmaceutical companies. Across key chronic disease specialties, the platform integrates medication guidance, patient education and full-course disease management into everyday services, supporting broader access to innovative treatments while strengthening its professional chronic care capabilities.

In the second half of 2026, Fangzhou will further advance its strategy as a full-lifecycle personal health service partner, expanding the XS LLM and its portfolio of AI-powered services across more healthcare scenarios. The Company will also deepen collaboration with pharmaceutical partners and strengthen specialty-care capabilities, helping to build a reliable, patient-centered health service ecosystem that supports patients throughout their health journey.

About Fangzhou Inc.

Fangzhou Inc. (HKEX: 06086) is China’s leading online chronic disease management platform, serving 59.8 million registered users and 282,000 physicians (as of June 30, 2026). The Company specializes in delivering tailored medical care and AI‑enabled precision medicine solutions. For more information, visit https://investors.jianke.com.

Media Contact

For further inquiries or interview requests, please contact:

Xingwei Zhao
Director of Public Relations
Email: pr@jianke.com

Disclaimer: This press release contains forward‑looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements.

Oma Savings Bank Plc, stock exchange release, 25 September 2026 at 4.30 p.m. (EEST), other information disclosed to the rules of the exchange

Oma Savings Bank Plc issues a covered bond of EUR 200 million as part of a bond program

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA OR SUCH OTHER COUNTRIES OR OTHERWISE IN SUCH CIRCUMSTANCES IN WHICH THE OFFERING OF THE NEW NOTES, THE TENDER OFFER OR THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Oma Savings Bank Plc (“OmaSp” or the “Company”) issues a covered bond of EUR 200 million. The maturity date of the bond is 2 October 2029, and the loan has a floating interest rate. The ISIN code of the bond is FI4000615059.

The loan issuance will take place under OmaSp’s EUR 4 billion bond program. On 1 September 2026, the Finnish Financial Supervisory Authority approved the base prospectus in respect of OmaSp’s bond program, and the supplement thereto on 21 September 2026.

The base prospectus, the supplement and the final terms of the bond are available in English on the Company’s website at https://www.omasp.fi/investors.

OmaSp has submitted an application for the bond to be admitted to trading on the regulated market maintained by Nasdaq Helsinki Ltd.

Oma Savings Bank Plc

Additional information:
Karri Alameri, CEO, tel. +358 20 758 3040, karri.alameri@omasp.fi
Sarianna Liiri, CFO, tel. +358 40 835 6712, sarianna.liiri@omasp.fi
Pirjetta Soikkeli, CCO, tel. +358 40 750 0093, pirjetta.soikkeli@omasp.fi

DISTRIBUTION:
Nasdaq Helsinki Ltd
Major media
www.omasp.fi

OmaSp is a solvent and profitable Finnish bank. About 600 professionals provide nationwide services through OmaSp’s 48 branch offices and digital service channels to over 200,000 private and corporate customers. OmaSp focuses primarily on retail banking operations and provides its clients with a broad range of banking services both through its own balance sheet as well as by acting as an intermediary for its partners’ products. The intermediated products include credit, investment and loan insurance products. OmaSp is also engaged in mortgage banking operations.

OmaSp core idea is to provide personal service and to be local and close to its customers, both in digital and traditional channels. OmaSp strives to offer premium level customer experience through personal service and easy accessibility. In addition, the development of the operations and services is customer oriented. The personnel is committed and OmaSp seeks to support their career development with versatile tasks and continuous development. A substantial part of the personnel also own shares in OmaSp.

AS LHV Group announces that during the period 18 to 24 September 2026, it has acquired the company’s own shares on the Nasdaq Tallinn Stock Exchange as follows:

Date Aggregated volume (pcs) Weighted average price per day (EUR)
18.09.2026 19,800 3.31
21.09.2026 20,100 3.31
22.09.2026 26,800 3.30375
23.09.2026 20,400 3.295
24.09.2026 26,800 3.2925

LHV Group is acquiring its own shares based on the resolution of the company’s general meeting of shareholders held on 26 March 2025, and under the conditions decided by the Supervisory Board. The authorized agent for the transactions is AS LHV Pank. Summary data of the acquisitions will be disclosed no later than on the seventh trading day after the transaction and will be made available to the Financial Supervision and Resolution Authority, via the Nasdaq Tallinn system, and on LHV Group’s investor website.

LHV Group is the largest domestic financial group and capital provider in Estonia. LHV Group’s main subsidiaries are LHV Pank, LHV Varahaldus, LHV Kindlustus and LHV Bank Limited. The Group employs nearly 1,200 people. LHV’s banking services are used by more than 514,000 customers, LHV-managed II pillar pension funds have 105,000 active customers and LHV Kindlustus provides insurance protection to 244,000 customers. LHV Bank, a subsidiary of LHV Group, holds a UK banking licence and offers banking services to international financial technology companies, loans to small and medium-sized enterprises and retail banking services.


Investor Relations

Sten Hans Jakobsoo
Head of Investor Relations and Corporate Development
Email: stenhans.jakobsoo@lhv.ee

Communications
Paul Pihlak
Head of Communications
Email: paul.pihlak@lhv.ee 

SANTIAGO, Chile, Sept. 25, 2026 (GLOBE NEWSWIRE) — You are cordially invited to participate in Banco Santander Chile’s (NYSE: BSAC) conference call-webcast on Wednesday November 4, 2026, at 11.00 AM Chile time (9.00 AM ET) where we will discuss 3Q 2026 financial results. The Bank’s Officers participating in the conference call are: Patricia Pérez, CFO, Cristian Vicuña, Chief Strategy Officer & Head of IR and Andres Sansone, Chief Economist. A question and answer session will follow the presentation.

The Management Commentary report will be published on October 30, 2026, before the market opens. The quiet period begins on October 16.

To participate, the webcast presentation can be viewed at: https://mm.closir.com/slides?id=720987

Or please dial in using any of the below numbers:
United Kingdom +44 203 984 9844
USA +1 718 866 4614
Austria +43 720 022981
Brazil +556120171549
Canada +1 587 855 1318
Chile +56228401484
Czech Republic +420 910 880101
Estonia +372 609 4102
Finland +35 8753 26 4477
France +33 1758 50 878
Germany +49 30 25 555 323
Hong Kong +852 3001 6551
Mexico +52 55 1168 9973
Peru +51 1 7060950
Poland +48 22 124 49 59
Russia +7 495 283 98 58
Singapore +65 3138 6816
South Africa +27872500455
South Korea +82 70 4732 5006
Sweden +46 10 551 30 20
Turkey +90 850 390 7512
Ukraine +380 89 324 0624

Participant Passcode: 720987
Please dial in approximately 10 minutes prior to the starting time of the conference.

If you have any questions, please contact Cristian Vicuña at Banco Santander Chile at Cristian.vicuna@santander.cl, Rowena Lambert at Rowena.lambert@santander.cl or Claudia Villalon at claudia.villalon@santander.cl

CONTACT INFORMATION

Cristian Vicuña
Investor Relations
Banco Santander Chile
Bandera 140, Floor 20
Santiago, Chile
Email: irelations@santander.cl
Website: www.santander.cl

About Santander

Banco Santander Chile is one of the companies with the highest risk ratings in Latin America, with an A2 rating from Moody’s, A- from Standard & Poor’s, A+ from the Japan Credit Rating Agency, and AA- from HR Ratings. All ratings have a stable outlook as of the date of this report.

As of June 30, 2026, the Bank has total assets of CLP 70,323,331 million (US$ 76,348million), total gross loans (including loans owed by banks) at amortized cost of CLP 41,426,628 million (US$ 44,976 million), total deposits of CLP 32,390,791 million (US$ 35,166 million), and shareholders’ equity of CLP 4,974,214 million (US$ 5,400 million). The BIS capital ratio is 16.6%, with a core capital ratio of 11.1%. As of June 30, 2026, Santander Chile employs 8,315 people and has 224 branches throughout Chile.

Company to feature surgeon-led educational programming and technologies supporting liver surgery

CUSA MicroFrance

CUSA Clarity Laparoscopic Tip and  MicroFrance Laparoscopic Bipolar Forceps - precision, handmade instruments created with the notion that Millimeters of Accuracy matter.
CUSA Clarity Laparoscopic Tip and MicroFrance Laparoscopic Bipolar Forceps – precision, handmade instruments created with the notion that Millimeters of Accuracy matter.

PRINCETON, N.J., Sept. 25, 2026 (GLOBE NEWSWIRE) — Integra LifeSciences (Nasdaq: IART) will mark 20 years of CUSA® technology within its portfolio at the American College of Surgeons (ACS) Clinical Congress 2026, taking place September 26-29 in Washington, D.C. The company will feature surgeon-led educational programming focused on liver surgery, including presentations and clinical discussions featuring the CUSA Clarity Ultrasonic Surgical Aspirator System and MicroFrance® laparoscopic surgical instrumentation.

As part of ACS’s Innovation Theater programming, Integra LifeSciences will feature presentations from internationally recognized liver surgeons to share clinical perspectives and experience with approaches to complex liver procedures. With more than 800,000 people diagnosed with liver cancer worldwide each year1, continued education and collaboration in liver surgery remain important for the treatment of patients with complex hepatobiliary conditions, including liver tumors.

Presenters include:

  • Goro Honda, M.D., Ph.D., FACS, Department of Surgery, Institute of Gastroenterology, Tokyo Women’s Medical University
  • Adnan Alseidi, M.D., M.Ed., M.B.A., FACS, professor of surgery, University of California, San Francisco (UCSF) and specialist in liver, pancreas and biliary surgery

“The ACS Congress provides an important opportunity to engage with the surgical community and exchange perspectives,” said Harvinder Singh, executive vice president and president, Specialty Surgery, Integra LifeSciences. “As we mark 20 years of CUSA within the Integra LifeSciences portfolio, we are proud of the role this technology plays in supporting surgeons globally. Integra LifeSciences remains focused on building upon proven technologies while addressing evolving clinical needs.”

Conference attendees are invited to visit Integra LifeSciences at Booth 428 and participate in the company’s Innovation Theater programming.

About CUSA® Clarity Ultrasonic Surgical Aspirator System

The CUSA Clarity Ultrasonic Surgical Aspirator System is indicated for use in surgical procedures where fragmentation, emulsification and aspiration of soft and hard (e.g. bone) tissue is desirable, such as neurosurgery, plastic and reconstructive surgery, orthopedic surgery, thoracic surgery, laparoscopic surgery, gynecological surgery, cardiac surgery and liver resection and transplant surgery.

About MicroFrance® Laparoscopic Instruments

The MicroFrance® laparoscopic manual surgical instruments are intended for use in a wide variety of surgical procedures, including laparoscopic and endoscopic procedures. The instruments are intended to scrape, cut, grasp, hold, remove, or manipulate tissue or structures.

About Integra LifeSciences

Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies is trusted by healthcare professionals to deliver transformative care. For the latest news and information about Integra LifeSciences and its products, please visit www.integralife.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on current expectations and projections and involve inherent risks, assumptions and uncertainties that are difficult to predict and which may be beyond our control. These forward-looking statements include, but are not limited to, statements related to the potential applications and efficacy of the Integra LifeSciences products described herein and the realization of improvements to health outcomes. There can be no assurance that previously observed benefits will be replicated. The actual effect of the use of these products can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. In addition, there can be no assurance that these products will achieve or maintain commercial success. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Integra LifeSciences’ business, particularly those identified under the headings “Risk Factors” and “Special Note Regarding Forward-Looking Statements,” included in Integra LifeSciences’ Annual Report on Form 10-K for the year ended December 31, 2025, and information contained in subsequent filings with the Securities and Exchange Commission. The forward-looking statements included in this news release are made only as of the date of this news release and Integra LifeSciences undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Investor Relations Contact:
Chris Ward
(609) 772-7736
chris.ward@integralife.com

Media Contact:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com

_______________________
1 American Cancer Society. Key Statistics About Liver Cancer. Updated Jan. 13, 2026. Accessed Sept. 23, 2026. American Cancer Society liver cancer statistics. [cancer.org]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/17d68748-4f8c-49e3-9da4-8f181ede652b

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.